Drug intelligence / Profile preview

ALM0106

Development stage: Preclinical
Lead developer: Alchemedicine
Modality: Small Molecules
Administration: Oral

Overview

ALM0106 is a preclinical-stage small molecule endothelin A (ETA) receptor antagonist developed by Alchemedicine for the treatment of inflammatory bowel disease (IBD). The program is currently under exclusive evaluation and negotiation for licensing by Merak-Dubhe TX. As an ETA receptor antagonist, ALM0106 is designed to modulate the endothelin system, which plays a role in intestinal inflammation and tissue remodeling. The drug is intended for oral administration, aligning with Alchemedicine's focus on developing convenient small molecule therapies for chronic inflammatory conditions.

Other names: ALM0106ALM-0106ALM 0106

Targets

EDNRA (Endothelin receptor type A)

Beyond the preview

Go deeper on ALM0106.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALM0106.

Explore the full profile